New hope for liver metastases: Y-90 radiation before surgery may boost candidacy
NCT ID NCT05195710
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 1 trial is testing whether injecting tiny radioactive beads (Y-90) into the right side of the liver can shrink tumors and make the left side grow larger, so more patients with colorectal cancer liver metastases can have potentially curative surgery. The study will enroll 50 patients whose liver is too small for safe surgery. Researchers are primarily checking if the procedure is safe and feasible.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Yttrium-90 (Y-90) resin microspheres
- What this could lead to
- If successful, this approach could make more patients eligible for curative liver surgery by shrinking tumors and growing healthy liver tissue.
- What could go wrong
- This is an early phase 1 trial with only 50 participants, so safety and feasibility are still being tested. The procedure may not work for everyone and carries risks like radiation damage to healthy tissue.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2022
- Expected to finish
-
Mar 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Borderline resectable unresectable (due to insufficient liver volume at presentation) colorectal liver metastases with potential curative intent, as determined by the surgeon and multidisciplinary team * Anticipated standardized FLR (sFLR) that would require right portal vein embolization (PVE) to increase the sFLR prior to either a single major hepatectomy, or prior to the second stage hepatectomy as part of a two-stage hepatectomy strategy, all in the setting of curative-intent resection(s). This evaluation will be documented in the clinical chart * Received at least four cycles (or two months) of chemotherapy * Willing, able and mentally competent to provide written informed consent * Medically and physically operable as determined by the surgeon Exclusion Criteria: * Extrahepatic disease that precludes intended curative intent treatment sequencing (treatable primary tumor and lung metastases allowed). "Treatable" is defined as having an intended future plan for local therapy (surgery, radiation, or ablation) as determined by the patient's medical oncologist and surgical oncologist * Projected sFLR before Y-90 of \<20% (starting with sFLR that is unrealistic for improvement to ≥30%) * Performance status limitations (Karnofsky \<80%, ECOG \>1) * Portal hypertension and/or cirrhosis * Starting total bilirubin \>1.3 mg/dL (except if patient has Gilbert's Disease) * CEA \>200 after 4 cycles of chemotherapy upon restaging visit * Clinical progression of disease on imaging and/or tumor marker after 4 cycles of chemotherapy that is clinically judged by surgical oncology and medical oncology to preclude surgical resection * Platelet count \<100,000/µL * Albumin \<3.5 g/dl * Symptomatic primary colon or rectal cancer (without pre-existing proximal diverting ostomy) * Pregnant or breast-feeding patient * Other medical or clinical contraindications to liver surgery * Non-English-speaking participants
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Metastases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Drug duo aims to tackle tough lung cancers after first treatment fails
- New radiation method aims to shrink large tumors better
- New drug 'Unmasks' cancer cells to immune system in early trial
- New combo therapy aims to stop liver cancer spread in its tracks
- Exercise program aims to boost strength and quality of life in advanced breast cancer
- New PET scan could outshine CT for kidney cancer staging